| River's Bend, P.c. | |
|
850 Stephenson Hwy Ste 210 Troy MI 48083-1151 | |
| (248) 585-3239 | |
| (248) 616-9759 |
| Full Name | River's Bend, P.c. |
|---|---|
| Speciality | Counselor |
| Location | 850 Stephenson Hwy Ste 210, Troy, Michigan |
| Authorized Official Name and Position | Amy Lee Buchanan (BUSINESS MANAGER) |
| Authorized Official Contact | 2485853239 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| River's Bend, P.c. 33975 Dequindre Rd Ste 5 Troy MI 48083-4649 Ph: (248) 585-3239 | River's Bend, P.c. 850 Stephenson Hwy Ste 210 Troy MI 48083-1151 Ph: (248) 585-3239 |
| NPI Number | 1265520209 |
|---|---|
| Provider Enumeration Date | 10/11/2006 |
| Last Update Date | 10/29/2020 |
| Certification Date | 10/29/2020 |
| Medicare PECOS PAC ID | 1052302874 |
|---|---|
| Medicare Enrollment ID | O20040526000958 |
News Archive
There have been many studies that have shown that your health is greatly affected by how you react to stressful events in life-setbacks or deadlines at work, conflicts and losses at home.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265520209 | NPI | - | NPPES |
| Provider Name | Aloha A Vancamp |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1437221934 PECOS PAC ID: 3072508597 Enrollment ID: I20040415000566 |
News Archive
There have been many studies that have shown that your health is greatly affected by how you react to stressful events in life-setbacks or deadlines at work, conflicts and losses at home.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
› Verified 3 days ago
| Provider Name | Bruce E Goldberg |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1336297449 PECOS PAC ID: 3476571696 Enrollment ID: I20051107000456 |
News Archive
There have been many studies that have shown that your health is greatly affected by how you react to stressful events in life-setbacks or deadlines at work, conflicts and losses at home.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
› Verified 3 days ago
| Provider Name | Karen J Willis |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1760608517 PECOS PAC ID: 5193811594 Enrollment ID: I20071017000178 |
News Archive
There have been many studies that have shown that your health is greatly affected by how you react to stressful events in life-setbacks or deadlines at work, conflicts and losses at home.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
› Verified 3 days ago
| Provider Name | Paul I Kowalski |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1326403411 PECOS PAC ID: 6103183181 Enrollment ID: I20171129001641 |
News Archive
There have been many studies that have shown that your health is greatly affected by how you react to stressful events in life-setbacks or deadlines at work, conflicts and losses at home.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
› Verified 3 days ago
| Provider Name | Jessica Lynn Hillen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609126697 PECOS PAC ID: 1153701446 Enrollment ID: I20220705000581 |
News Archive
There have been many studies that have shown that your health is greatly affected by how you react to stressful events in life-setbacks or deadlines at work, conflicts and losses at home.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
› Verified 3 days ago
News Archive
There have been many studies that have shown that your health is greatly affected by how you react to stressful events in life-setbacks or deadlines at work, conflicts and losses at home.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
› Verified 3 days ago
Hope Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 38815 Dequindre, Suite 103, Troy, MI 48083 Phone: 248-250-7343 Fax: 248-740-7772 | |
Perspectives Of Troy, P.c. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 888 W Big Beaver Rd Ste 1450, Troy, MI 48084 Phone: 248-322-0003 Fax: 248-244-1330 | |
Better Mental Health, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 W Big Beaver Rd, Suite 200, Troy, MI 48084 Phone: 248-703-6039 Fax: 248-680-6699 | |
Naomi Casement Lmsw, Caadc Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2265 Livernois Rd, Suite 260, Troy, MI 48083 Phone: 810-964-5400 Fax: 586-510-4800 | |
Diamond Cunseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 888 W Big Beaver Rd Ste 780, Troy, MI 48084 Phone: 586-217-3245 | |
Rich Blessings Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 W Big Beaver Rd Ste 1402, Troy, MI 48084 Phone: 248-561-3237 | |
Lillybrook Counseling Services Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 667 E Big Beaver Rd Ste 107, Troy, MI 48083 Phone: 248-250-6620 Fax: 248-250-6629 |